According to this newspaper, in current clinical practice, the treatment of type 2 diabetes often relies heavily on the traditional approach of "gradually increasing medication." Many patients only enter a more potent treatment phase after their blood sugar has been poorly controlled for a long time and the risk of complications has gradually accumulated.
　　However, in recent years, discussions surrounding early diabetes management have been undergoing a significant shift. A growing body of research suggests that the choice of treatment starting point not only affects short-term glycemic control but also profoundly relates to patients' long-term complication risk and overall prognosis. Clinical management strategies for type 2 diabetes are shifting from a "late-stage reinforcement" approach to a new paradigm of "intervention at the starting point."
　　February 11th, ReiThe innovative dual-target drug Mufengda® (Telborpeptide Injection) has been approved by the China National Medical Products Administration for monotherapy in adults with type 2 diabetes mellitus (T2DM). This approval marks a significant step forward for the drug, moving it from combination therapy to other treatment options.The complete evidence-based approach, starting with monotherapy, provides Chinese patients with early-stage diabetes with a new treatment option that is "effective from the outset".
　　This approval is based on the SURPASS-CN-MONO study, which was specifically conducted for early-stage type 2 diabetes mellitus (T2DM) patients in China. The study was led by Professor Mu Yiming, Director of the Department of Endocrinology at the General Hospital of the Chinese People's Liberation Army, and covered 28 research centers across the country, including more than 200 adult T2DM patients in China.
　　The study results showed that after 40 weeks of treatment, patients achieved clinically significant improvements in blood glucose levels and weight, while no increased risk of hypoglycemia was observed.
　　Mu Yiming pointed out that early blood glucose control is crucial for the long-term management of diabetic patients. "For diabetic patients, good early blood glucose control is the cornerstone of scientifically managing chronic diseases and improving quality of life, laying a solid foundation for reducing the risk of long-term complications."
　　This assessment also reflects the current challenges facing diabetes management in my country. Public data shows that nearly half of Chinese diabetes patients do not meet the standard for blood glucose control (HbA1c ≥ 7.0%). Previous studies have shown that early comprehensive management of blood glucose and weight in newly diagnosed type 2 diabetes patients helps slow disease progression. The approval of telpoxetine monotherapy provides clinicians with a powerful and simplified new tool for proactive intervention during this window of opportunity.
　　As telpolide gradually accumulates evidence-based support in various treatment scenarios, including as a monotherapy, in combination with oral hypoglycemic agents, and in combination with insulin, its seamless application at different stages of the disease provides more continuous options for clinical practice.
　　Eli Lilly Vice President and General Manager of China, De Helan, said: "This approval for monotherapy will give 148 million Chinese patients with type 2 diabetes the opportunity to receive a globally effective treatment at the initial treatment stage. This simplified treatment will reduce the burden of multiple medications for patients, achieve disease control earlier, and move the window for complication prevention forward, ultimately improving long-term outcomes and reducing the social burden of chronic diseases."
https://finance.eastmoney.com/a/202602123649125515.html